Pharmacokinetics study of irinotecan and sn-38 by coadministered thalidomide
- At: 2010 FIP Congress in Lisbon (Portugal)
- Type: Poster
- By: SHI, Aixin (Department of pharmacy,Beijing Hospital, Beijing, China)
- Co-author(s): Hu, Xin (Department of pharmacy,Beijing Hospital, BEIJING, China)
Hu, Yanling (Department of pharmacy,Beijing Hospital, BEIJING, China)
BACKGROUND: Irinotecan(CPT-11) is a broad-spectrum antineoplastic agent. The clinical use of CPT-11 is hindered by dose-limiting diarrhea. SN-38 is an active metabolite of CPT-11, delayed diarrhea could be reduced if the concentration of SN-38 was decreased. It has been confirmed the intestinal toxicity of CPT-11 was relieved by coadministrated.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.